| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA1823559
Max Phase: Preclinical
Molecular Formula: C15H15N3O5
Molecular Weight: 317.30
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: O=C(O)[C@]1(O)C=C(c2cn(-c3ccccc3)nn2)[C@@H](O)[C@H](O)C1
Standard InChI: InChI=1S/C15H15N3O5/c19-12-7-15(23,14(21)22)6-10(13(12)20)11-8-18(17-16-11)9-4-2-1-3-5-9/h1-6,8,12-13,19-20,23H,7H2,(H,21,22)/t12-,13-,15+/m1/s1
Standard InChI Key: FLIDIIDIPNIAQH-NFAWXSAZSA-N
Associated Targets(non-human)
aroQ 3-dehydroquinate dehydratase (62 Activities)
aroQ 3-dehydroquinate dehydratase (29 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
aroQ 3-dehydroquinate dehydratase (50 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 317.30 | Molecular Weight (Monoisotopic): 317.1012 | AlogP: -0.41 | #Rotatable Bonds: 3 |
| Polar Surface Area: 128.70 | Molecular Species: ACID | HBA: 7 | HBD: 4 |
| #RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 3.19 | CX Basic pKa: | CX LogP: 0.01 | CX LogD: -3.44 |
| Aromatic Rings: 2 | Heavy Atoms: 23 | QED Weighted: 0.61 | Np Likeness Score: -0.18 |
References
| 1. Tizón L, Otero JM, Prazeres VF, Llamas-Saiz AL, Fox GC, van Raaij MJ, Lamb H, Hawkins AR, Ainsa JA, Castedo L, González-Bello C.. (2011) A prodrug approach for improving antituberculosis activity of potent Mycobacterium tuberculosis type II dehydroquinase inhibitors., 54 (17): [PMID:21780742] [10.1021/jm2006063] |
| 2. Tran AT, Cergol KM, Britton WJ, Imran Bokhari SA, Ibrahim M, Lapthorn AJ, Payne RJ. (2010) Rapid assembly of potent type II dehydroquinase inhibitors viaClick chemistry, 1 (4): [10.1039/C0MD00097C] |
Source
Source(1):